Close Menu

The Scan

In PNAS this week: study of gene mutation implicated in deafness, examination of codon origins, and more.

An initial analysis of early data from Pfizer and BioNTech's COVID-19 vaccine trial indicates it is 90 percent effective, the Washington Post reports.

But, Again, Maybe Not

An FDA advisory panel has determined there isn't enough data to gauge whether a new Alzheimer's disease drug works, according to NPR. reports Cathy Foley, an applied physicist, is to be Australia's next chief scientist.

In PLOS this week: differential transcript usage and splicing among Parkinson's disease patients, search for markers of intracranial aneurysms, and more.

In Science this week: environmental influences on the protein-coding genome of marine microbes, and more.

Sent Out Anyway

NPR reports that CDC officials were aware of problems with its initial SARS-CoV-2 test before the test was sent out.

Spectrum reports that a clinical trial of a gene therapy for Angelman syndrome is on hold.

In Minks, In People

Denmark reacts to a mutated SARS-CoV-2 strain found among minks also being detected in a dozen people, the Associated Press reports.

Stuff reports that genomic testing has linked a case of COVID-19 affecting a New Zealand healthcare worker to a quarantined group.

Science reports on how scientists running for office in the US have fared in the election, though some results are still being counted

Test for Both

The Associated Press reports South Korea has approved a test that detects both the SARS-CoV-2 and seasonal influenza viruses.

In Nature this week: sequence of the Gala apple and two of its wild relatives, analysis of SARS-CoV-2 genomes highlights role of US travelers and superspreaders in transmission in Israel, and more.

Slovakia tested about two-thirds of its population for SARS-CoV-2 last weekend, finding just more than 1 percent of the population was positive, NPR reports.

Seems to Support

According to Stat News, US regulators appear to have a favorable view of Biogen's Alzheimer's disease therapy.

The Guardian reports that AstraZeneca and Oxford University's coronavirus vaccine will likely not be ready for distribution by late December.

In Cell this week: SARS-CoV-2 evolution and spread in North Carolina, protein and other features that distinguish mild and severe COVID-19, and more.

All of Liverpool

A pilot program for mass COVID-19 testing is to start in Liverpool, Sky News reports.

An analysis suggests rapid SARS-CoV-2 tests may have drawbacks under real-world conditions, the New York Times reports.

The Scientist reports a blood test for Alzheimer's disease is now available in many US states.

In PNAS this week: genetic diversity and more among Nipah viruses, glycome expression study of the brain, and more.

The New York Times had geneticists sequence SARS-CoV-2 samples from two journalists who contracted the virus while covering the White House.

Three US agencies warn of ransomware attacks aimed at hospitals, CBS News reports.

The Guardian writes that researchers are examining whether small genetic changes account for the different COVID-19 disease courses people experience.

In PLOS this week: gene expression in muscle stem cells, blood metabolomic study of diabetic retinopathy complications, and more.


Bloomberg reports AstraZeneca may conduct another study of its candidate SARS-CoV-2 vaccine after dosing error.

Moderna is applying for an Emergency Use Authorization for its coronavirus vaccine, according to the New York Times.

The National Health Service is to conduct a trial of Grail's blood-based screening test for cancer.

In PLOS this week: somatic mutation patterns of glioblastomas among Lebanese patients, phenome-wide study using UK Biobank data, and more.